聚合物纳米粒在抗年龄相关性黄斑变性中的研究进展  

Progress of Polymer Nanoparticles for Combating Age-Related Macular Degeneration

作　　者：丛会婧 胡静 王婧 刘佳欣 唐景玲[1] CONG Huijing;HU Jing;WANG Jing;LIU Jiaxin;TANG Jingling(School of Pharmacy,Harbin Medical University,Harbin 150086,China)

机构地区：[1]哈尔滨医科大学药学院,哈尔滨150086

出　　处：《中国药学杂志》2024年第20期1925-1930,共6页Chinese Pharmaceutical Journal

基　　金：黑龙江省博士后基金资助(LBH-Z20177);哈尔滨医科大学药学院杰出青年基金资助(2019-JQ-03)。

摘　　要：年龄相关性黄斑变性(age-related macular degeneration, AMD)是一种退行性视网膜疾病,AMD主要又分为两种形式:干性(萎缩性)和湿性(渗出性)。玻璃体内注射抗血管内皮生长因子药物是最常用的治疗湿性AMD的方法,然而该方法仅能缓解并不能根治,且部分患者并不适应该给药方式。纳米技术的应用为改善AMD的药物输送提供了新的策略,其中聚合物纳米粒可提供持续的药物释放,经修饰可靶向病变部位并增加药物靶部位沉积,穿透眼部屏障延长药物滞留时间。本文综述了基于聚合物纳米粒治疗AMD的药物递送系统的研究进展,为AMD的治疗提供可行性参考。Age-related macular degeneration(AMD)is a degenerative retinal disease.AMD is divided into two major forms:dry(atrophic)AMD and wet(exudative)AMD.The most common treatment for wet AMD is intravitreal injection of anti-vascular endothelial growth factor drugs.However,the treatment can only relieve but not care,and there are some patients who aren’t adapted to this treatment of administration.The application of nanotechnology offers new strategies for improving drug delivery in AMD,where polymeric nanoparticles can provide sustained drug release,can be modified to target the lesion and increase drug target site deposition,can penetrate the ocular barrier and extend drug retention times.This paper reviews the current research advances in polymeric nanoparticles-based drug delivery systems for the treatment of AMD,providing a viable reference to the treatment of AMD.

关 键 词：年龄相关性黄斑变性 视网膜疾病 纳米技术 聚合物纳米粒 药物递送 

分 类 号：R944[医药卫生—药剂学]